STESteris Plc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Daniel A. Carestio

Location

N/A, Ireland

Exchange

NYSE

Website

https://steris.com

Summary

STERIS plc provides infection prevention and other procedural products and services worldwide.

Company Info

CEO

Daniel A. Carestio

Location

N/A, Ireland

Exchange

NYSE

Website

https://steris.com

Summary

STERIS plc provides infection prevention and other procedural products and services worldwide.

AI Insights for STE
5 min read

Quick Summary

STERIS plc is an Ireland-domiciled medical equipment and infection prevention company listed on the NYSE under the ticker STE. The company provides products and services that help hospitals, ambulatory surgery centers, pharmaceutical manufacturers, biotechnology companies, medical device makers, laboratories, and research organizations reduce contamination risk and maintain sterile environments. Its business is organized around Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment sells sterilizers, washers, cleaning chemistries, sterility assurance products, and accessories used in sterile processing departments and GI procedures. The Applied Sterilization Technologies business provides outsourced sterilization and related services for medical devices, pharmaceuticals, and other regulated products. The Life Sciences segment serves pharmaceutical and biotech customers with consumable cleaning chemistries, washer disinfectors, and contamination-control solutions used in controlled production environments.

Strengths

•

STERIS’s primary strength is its specialized position in infection prevention, sterilization, and procedural support markets.

•

These are mission-critical areas because hospitals, pharmaceutical companies, biotechnology firms, and medical device manufacturers must follow strict contamination-control standards.

•

The company benefits from a mix of capital equipment, recurring consumables, service contracts, and outsourced sterilization services, which can create durable customer relationships.

•

Its gross profit of 684.2 million on 1.4927 billion of quarterly revenue suggests a strong margin structure for its product and service portfolio.

•

STERIS also has a global presence, 16,000 employees, and a market capitalization of about 22.64 billion, giving it meaningful scale.

Key Risks

•

STERIS faces execution risk because its premium valuation leaves limited room for disappointment.

•

A slowdown in hospital capital spending could reduce demand for sterilizers, washers, and other large equipment purchases.

•

Regulatory changes, compliance failures, product recalls, or quality issues could harm the company’s reputation and financial results because its products operate in highly regulated healthcare and life sciences environments.

•

Competition from companies such as Getinge, Belimed, 3M, Ecolab, and ASP could pressure pricing, margins, or market share.

What to Watch

During the most recent reported quarter, STERIS generated operating revenue of 1.4927 billion and total revenue of the same amount.
Gross profit was 684.2 million, which indicates a solid gross margin profile for a specialized medical equipment and services company.
Operating income was 285.8 million, showing that the company remained profitable after operating expenses.
Net income was 201 million, and diluted EPS was 7.93 based on the provided data.
The company continued to operate through its Healthcare, Applied Sterilization Technologies, and Life Sciences segments, with no specific product launch or acquisition identified in the supplied news feed.
The available recent news items do not appear to include a STERIS-specific partnership, controversy, acquisition, or product announcement for the quarter.

Price Drivers

•

STERIS’s stock price is primarily driven by earnings growth, margins, healthcare procedure volumes, demand for sterilization services, and investor expectations for recurring revenue.

•

The company reported Basic EPS of 7.97 and Diluted EPS of 7.93, while its price-to-earnings ratio is about 28.13, meaning the market is assigning a premium valuation to the business.

•

Quarterly operating revenue was 1.4927 billion with gross profit of 684.2 million, operating income of 285.8 million, and net income of 201 million, so investors will watch whether margins continue to hold.

•

Valuation metrics such as EV to EBITDA of 14.74, EV to revenue of 4.01, and EV to free cash flow of 29.39 suggest expectations for stable growth and high-quality cash generation.

•

Macro factors such as hospital capital spending, interest rates, regulatory requirements, healthcare utilization, and life sciences funding can also influence the share price.

•

The stock’s beta of 0.925 suggests it is slightly less volatile than the broader market, but its premium valuation could still react sharply to any earnings disappointment.

Recent News

•

The supplied recent news feed does not include a direct company-specific announcement about STERIS.

•

Most of the provided news items discuss unrelated companies or industries, including UPS, Novo Nordisk, Adobe, TSMC, Nvidia, Broadcom, Monster Beverage, Apple, and several private consumer or technology businesses.

•

Therefore, there is no clear recent STERIS partnership, controversy, acquisition, product launch, or management update available from the provided news set.

•

Based on the fundamental data, the most relevant current company information is its latest reported revenue, profitability, valuation, and upcoming earnings date.

•

Investors should avoid treating the unrelated news items as direct catalysts for STE.

•

The absence of specific company news means the stock is likely being driven more by fundamentals, sector sentiment, healthcare demand, valuation, and upcoming earnings expectations.

Market Trends

•

STERIS is influenced by several broad market trends in healthcare, medical equipment, and life sciences.

•

Infection prevention remains a durable priority for hospitals, surgical centers, pharmaceutical manufacturers, and medical device companies.

•

Aging populations, surgical procedure demand, and healthcare system modernization can support long-term demand for sterilization equipment and related services.

•

At the same time, hospital budget pressure and higher financing costs can delay capital equipment purchases, which may create uneven quarterly order patterns.

•

Outsourcing trends can benefit STERIS’s Applied Sterilization Technologies business because customers may prefer specialized providers for complex sterilization needs.

•

Life sciences demand can be cyclical because biotech funding, pharmaceutical manufacturing investment, and facility expansion projects can rise or fall depending on capital markets and drug development pipelines.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on STE

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@ProduceCut309 6 months ago

What to Expect From $STE Q1 Earnings

What to Expect From $STE Q1 Earnings

is heading into Q1 earnings with steady expectations, as investors look for consistent demand in medical devices and sterilization services. The company has benefited from stable healthcare spending and recurring service revenue, which has helped support long-term growth even in a slower macro environment. The main focus this quarter is whether can keep margins stable while continuing to grow revenue at a moderate but reliable pace.

No more topics to show